Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for ilmn
-0.24 (-0.12%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 199.14 - 203.00
52 week 145.12 - 242.37
Open 201.00
Vol / Avg. 1.39M/1.64M
Mkt cap 29.19B
P/E 61.68
Div/yield     -
EPS 3.27
Shares 144.70M
Beta 0.96
Inst. own 98%
Oct 19, 2015
Q3 2015 Illumina Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 21, 2015
Q2 2015 Illumina Inc Earnings Call - Webcast
Jul 21, 2015
Q2 2015 Illumina Inc Earnings Release
Jun 10, 2015
Illumina Inc at Goldman Sachs Healthcare Conference
Jun 3, 2015
Illumina Inc at Bank of America Merrill Lynch Global Technology Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 18.96% 18.98%
Operating margin 28.17% 27.65%
EBITD margin - 29.49%
Return on average assets 11.39% 11.11%
Return on average equity 24.00% 23.59%
Employees 3,700 -
CDP Score - -


5200 Illumina Way
SAN DIEGO, CA 92122-4616
United States - Map
+1-858-2024500 (Phone)
+1-858-2024766 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Illumina, Inc. (Illumina) is engaged in production development of sequencing-and array-based solutions for genetic analysis. It offers integrated systems, consumables and analysis tools for genetic analysis. Illumina also manufactures sequencing and array platforms, reagent kits and scanning equipment. The Company's customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina's sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. The Company's products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics.

Officers and directors

William H. Rastetter Ph.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Francis A. deSouza President, Director
Age: 44
Bio & Compensation  - Reuters
Jay T. Flatley Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Marc A. Stapley Chief Financial Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
David R. Walt Ph.D. Chairman - Scientific Advisory Board, Independent Director
Age: 62
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Charles E. Dadswell Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Sanjay Chikarmane Senior Vice President, General Manager
Bio & Compensation  - Reuters
Nicholas J. Naclerio Ph.D. Senior Vice President, Corporate Development & General Manager - Enterprise Informatics
Age: 53
Bio & Compensation  - Reuters
Paul L. Bianchi Senior Vice President - Human Resources
Age: 53
Bio & Compensation  - Reuters